# Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years

> **NCT00616928** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 4561 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00616928
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01-23
- **Primary completion:** 2008-10-15
- **Final completion:** 2009-03-19
- **Target enrollment:** 4561 (ACTUAL)
- **Last updated:** 2018-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00616928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00616928, "Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00616928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*